{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:19:39Z","timestamp":1788542379252,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/ecco-jcc\/jjy063","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T15:08:11Z","timestamp":1525532891000},"source":"Crossref","is-referenced-by-count":30,"title":["Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab"],"prefix":"10.1093","author":[{"given":"Mar\u00eda Jos\u00e9","family":"Fobelo Lozano","sequence":"first","affiliation":[{"name":"Pharmacy Service, Valme University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-6395","authenticated-orcid":false,"given":"Reyes","family":"Serrano Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Valme University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Digestive Medicine Service, Valme University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"key\n\t\t\t\t20180605020719_CIT0001","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"key":"key\n\t\t\t\t20180605020719_CIT0002","first-page":"1693","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180605020719_CIT0003","first-page":"83","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t20180605020719_CIT0004","first-page":"2534","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180605020719_CIT0005","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"key":"key\n\t\t\t\t20180605020719_CIT0006","first-page":"E26","article-title":"A Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn\u2019s disease","volume":"143","author":"Targan","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180605020719_CIT0007","first-page":"104","article-title":"Yeasts: neglected pathogens","volume":"27","author":"Poulain","year":"2009","journal-title":"Dig Dis"},{"key":"key\n\t\t\t\t20180605020719_CIT0008","first-page":"310","article-title":"Proinflammatory cytokines underlying the inflammation of Crohn\u2019s disease","volume":"26","author":"Strober","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"key\n\t\t\t\t20180605020719_CIT0009","first-page":"291","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20180605020719_CIT0010","first-page":"1635","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20180605020719_CIT0011","first-page":"337","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20180605020719_CIT0012","first-page":"248","article-title":"Increased levels of circulating Th17 cells in quiescent versus active Crohn\u2019s disease","volume":"7","author":"Dige","year":"2013","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjy063\/25009275\/jjy063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T02:07:25Z","timestamp":1528164445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article\/doi\/10.1093\/ecco-jcc\/jjy063\/4994228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy063","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]}}}